Lactobacillus rhamnosus CRL1505


A randomized, double-blind, placebo-controlled trial with 298 pre-school children (2-5 years old) that consumed CRL 1505® (0,1 billion CFU/day) or a placebo 5 days/week for 6 months showed that children in the probiotic group had a significantly lower number of infections during the study period. CRL 1505® intake lowered the incidence of upper respiratory tract infections, pharyngitis, tonsillitis, and acute diarrhea. Additionally, kids in the probiotic group used less antibiotics.
One of the key elements identified in CRL 1505® interaction with the host is its heat-stable peptidoglycan (PG05), which has proven to have a strain-specific immunomodulatory activity. PG05 significantly increases specific antibodies production and the number of alveolar macrophages. These cells, during viral and bacterial infections, play a key role in the beneficial modulation of the respiratory innate immune response.
Lactobacillus rhamnosus CRL 1505® is given every day to more than 300,0000 children in Argentina as part of the official National Nutritional Program.

Scientific reference(s)


Additional info

Therapeutical area(s)

Immune system


Diarrhea · Immune stimulation


Scroll to Top
Browse companies by type
Brought to you by